Tencent has officially announced an update on the "WorkBuddy" tool, which can automatically generate daily and weekly reports.
On March 12th, Tencent's version of "WorkBuddy" welcomed a major update.
On March 12th, Tencent's "Crayfish" WorkBuddy welcomed a major update. This update supports direct connection to "Crayfish" WorkBuddy with one click in WeChat, adds support for enterprise WeChat long link access, and optimizes the stability of QQ, Feishu, and other IM links. As long as the computer is not turned off, WorkBuddy can run stably 24/7, ensuring real-time response to remote commands. In addition, WorkBuddy officially supports background automation tasks, which can automatically generate daily and weekly reports. Users only need to set up scheduled tasks, and the AI will automatically fetch work data, organize meeting minutes, monitor competitor information, and generate structured reports.
On March 9th, Tencent announced that the AI intelligent agent WorkBuddy had officially entered public testing. According to reports, WorkBuddy is fully compatible with OpenClaw skills, with over 20 Skills packages and MCP protocol built-in. It can be accessed through mainstream IM tools such as enterprise WeChat, Feishu, DingTalk, QQ, etc., allowing for direct remote scheduling of WorkBuddy on the computer. Prior to this, QQ and enterprise WeChat had announced support for integrating OpenClaw.
Related Articles

Wharf Holdings (00004) has announced its annual performance, with a profit of HKD 50 million attributable to shareholders, reversing losses from the previous year.

CITIC TELECOM (01883) announces annual financial results, with a net profit attributable to shareholders of HK$920 million, an increase of 1.1% year on year.

BAO PHARMA-B(02659): KJ101 received clinical trial approval for new indications.
Wharf Holdings (00004) has announced its annual performance, with a profit of HKD 50 million attributable to shareholders, reversing losses from the previous year.

CITIC TELECOM (01883) announces annual financial results, with a net profit attributable to shareholders of HK$920 million, an increase of 1.1% year on year.

BAO PHARMA-B(02659): KJ101 received clinical trial approval for new indications.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


